drugset / Trial / NCT01888003

The Benefits of a Preoperative Anemia Management Program

NCT01888003

Terminated 51 enrolled University of Alabama at Birmingham
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this study is to gain further insight into the comparative effectiveness of treating patients, who are found to be anemic before their elective surgery, with a series of weekly subcutaneous doses of a drug given before surgery, which stimulates the natural production of red blood cells (a so-called erythropoietic stimulating agent \[ESA\]) along with intravenous iron, in reducing the need for blood transfusions (donated by someone other than the patient) during and after adult total hip arthroplasty (hip replacement surgery). The effects of a Preoperative Anemia Management Program (PAMP) on the patient's quality of recovery, health-related quality of life, fatigue, and rehabilitation pattern after surgery will also be examined. A cost-effectiveness analysis will be performed to compare the cost of these commercially available, FDA-approved medications versus the cost of transfused blood

Timeline

Start
2013-04
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Iron sucrose Unknown 200 mg Intravenous
Comparator epoetin alfa Protein / enzyme biologic 40000 iu Subcutaneous